Abstract
Thrombosis is a complex, multifactorial process characterized by partial or total occlusion of a vessel. In the arterial vascular tree, thrombosis is closely related to atherosclerosis, another complex process, characterized by the formation of an atheromatous plaque on the vascular wall.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
de Gaetano G, Cerletti C, Dejana E, Vermylen J (1986) Current issues in thrombosis prevention with antiplatelet drugs. Drugs 31: 517–549
de Gaetano G, Bertele V, Cerletti C (1987) Pharmacology of antiplatelet drugs. In: Maclntyre D.E. and Gordon J.L. (Eds) Platelets in biology and pathology III, Elsevier, Amsterdam pp 515–573
Antiplatelet Trialists’ Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296: 320–331
de Gaetano G (1988) Primary prevention of vascular disease by aspirin. Lancet 1: 1093–1094
Collins R, Scrimgeour A, Yusuf S, Peto R (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urology surgery. N Engl J Med 318: 1162–1173
GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet I: 379
ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,189 cases of suspected acute myocardial infarction. Lancet II: 349–360
Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665
Moncada S, Higgs EA, Vane JR (1977) Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet I: 18–20
Villa S, Mysliwiec M, de Gaetano G (1977) Prostacyclin and atherosclerosis in rats. Lancet II: 1216–1217
D’Angelo V, Villa S, Mysliwiec M, Donati MB, de Gaetano G (1978) Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost 39: 535–536
Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano G (1978) Bleeding in renal failure: Altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 22: 347–353
Remuzzi G, Cavenaghi AE, Mecca G, Donati MB, de Gaetano G (1977) Prostacyclin-like activity and bleeding in renal failure. Lancet II: 1195–1197.
Leithner CH, Winter M, Silbauer K, Wagner O, Pinggera W, Sinzinger H (1978) Enhanced prostacyclin availability of blood vessels in uraemic humans and rats. In: Robinson RHB, Hawkins JB (Eds) Dialysis transplantation nephrology. Proceedings of the 15th Congress of European Dialysis and Transplant Association. Tunbridge Wells: Pitman Medical, 418–422
Remuzzi G (1988) Bleeding in renal failure. Lancet I: 1205–1208
Remuzzi G (1988) Bleeding in renal failure. Lancet I: 1205–1208
Remuzzi G, Livio M, Cavenaghi AE, Marchesi D, Mecca G, Donati MB, de Gaetano G(1978) Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thromb Res 13: 531–536.
Maclntyre DE, Pearson JD, Gordon JL (1978) Localisation and stimulation of prostacyclin production in vascular cells. Nature 271: 549.
Donati MB, Misiani R, Marchesi D, Livio M, Mecca G, Remuzzi G, de Gaetano G (1980) Hemolytic-uremic syndrome, prostaglandins, and plasma factors. In: Remuzzi G, Mecca G, and de Gaetano G (Eds) Hemostasis, Prostaglandins and Renal Disease, Raven Press, New York: 283–290.
Remuzzi G (1987) Thrombotic thrombocytopenic purpura and allied disorders. In: Verstraete M, Vermylen J, Lijnen R and Arnout J (Eds) Thrombosis and Haemostasis, Leuven University Press, Leuven: 673–708
Ross R (1986) The pathogenesis of atherosclerosis - an update. N Engl J Med 314: 488–500
Ross R, Glomset J, Kariya B, Harker L (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71: 1207–1210
Calissano P, Cattaneo A, Biocca S, Aloe L, Mercanti D, Levi-Montalcini R (1984) The nerve growth factor. Established findings and controversial aspects. Exp Cell Res 154: 1–9
Gajdusek CM, Di Corleto PE, Ross R, Schwartz SM (1980) An endothelial cell-derived growth factor. J Cell Biol 85: 476–472
Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnowsky MJ (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol 90: 372– 379
Sporn MB, Roberts AB, Wakefield M, Assoian RK (1986) Transforming growth factor ß: biological function and chemical structure. Science 233: 532–534
Carpenter G, Zendegui JZ (1986) Epidermal growth factor, its receptors, and related proteins. Exp Cell Res 164: 1–10
Villa S, de Gaetano G (1977) Prostacyclin-like activity in rat vascular tissues. Fast, long- lasting inhibition by treatment with lysine acetylsalicylate. Prostaglandins 14: 1117–1124.
de Gaetano G, Cerletti C, Bertele V (1982) Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet II: 974–977
Bertele V, Falanga A, Tomasiak M, Dejana E, Cerletti C, de Gaetano G (1983) Platelet thromboxane synthetase inhibitors with low doses of aspirin: Possible resolution of the ‘aspirin dilemma’. Science 220: 517–519
Cerletti C, Gambino MC, Garattini S, de Gaetano G (1986) Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest 78: 323–326
Gambino MC, Passaghe S, Chen ZM, Bucchi F, Gori G, Latini R, de Gaetano G, Cerletti C (1988) Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portacaval shunt in rats. J Pharmacol Exp Ther 245: 287–290
Heiden D, Mielke CH Jr, Rodvien R (1977) Impairment by heparin of primary haemostasis and platelet (I4C)-hydroxytryptamine release. Br J Haematol 36: 427–436
Pangrazzi J, Abbadini M, Zametta M, Naggi A, Torri G, Casu B, Donati MB (1985) Antithrombotic and bleeding effects of low molecular weight heparin fraction. Biochem Pharmacol 34: 3305–3308
Casu B, Naggi A, Oreste P, Torri G, Pangrazzi J, Maggi A, Abbadini M, Donati MB (1987) Bleeding effects associated with heparin contaminants. Lancet I: 1088
Borowska A, Lauri D, Maggi A, Dejana E, de Gaetano G, Donati MB, Pangrazzi J (1987) Impairment of primary haemostasis by low molecular weight heparins in rats. Br J Haematol 68: 339–344
Nurden AT (1987) Platelet membrane glycoproteins and their clinical aspects. In: Verstraete M, Vermylen J, Lijnen R and Arnout J (Eds) Thrombosis and Haemostasis. Leuven University Press, Leuven: 93–125
Phillips DR, Charo IF, Parise LV, Fitzgerald L (1988) The platelet membrane glycoprotein Ilb-IIIa complex. Blood 71 831–843
Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmermann TS, Harker L (1988) Effects of monoclonal antibodies against the platelet glycoprotein lib/ Ila complex on thrombosis and hemostasis in the baboon. J Clin Invest 8: 149–158.
Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero L, Leinbach RC, Ziskind AA, Collen D (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77: 670–677
Humphries MJ, Olden K, Yamada KM (1986) A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233: 467–470
Harfenist EJ, Packham MA, Mustard JF (1988) Effects of the cell adhesion peptide, Arg- Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. Blood 71: 132–136
Poggi A, Mussoni L, Kornblihtt L, Ballabio E, de Gaetano G, Donati MB (1978) Warfarin enantiomers anticoagulation, and experimental tumor metastasis. Lancet I: 163–164
Colucci M, Delaini F, De Bellis Vitti G, Locati D, Poggi A, Semeraro N, Donati MB (1983) Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis Lung Carcinoma cells: role of vitamin K deficiency. Biochem Pharmacol 32: 1689–1691
Donati MB, Roncaglioni MC, Falanga A, Casali B, Semeraro N (1986) Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin? Haemostasis 16: 288–294
Falanga A, Bolognese AP, Casali B, Roncaglioni MC, Donati MB (1987) Several murine metastatising tumours possess a cysteine proteinase with cancer procoagulant characteristics. Int J Cancer 39: 774–777
Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG (1986) Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 46: 6471
Falanga A, Alessio MG, Donati MB, Barbui T (1988) A new procoagulant in acute leukemia. Blood 71: 870–875
Gordon SG, Hashiba U, Poole MA, Cross BA, Falanga A (1985) A cysteine proteinase procoagulant from amnion-chorion. Blood 66: 1261
Buchanan MR, Dejana E, Cazenave J-P, Richardson M, Mustard JF, Hirsh J (1980) Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. Thromb Res 20: 447–460
Dyerberg J, Bang HO (1979) Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet II: 433–435
Knapp HR, Reilly IAG, Alessandrini P, FitzGerald GA (1986) In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 314: 937–942
Grundy SM, Bonanome A (1987) Workshop on monounsaturated fatty acids. Arteriosclerosis 7: 644–648
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers, Dordrecht
About this chapter
Cite this chapter
de Gaetano, G., Cerletti, C., Poggi, A., Donati, M.B. (1990). Animal experiments and recent progress in thrombosis research. In: Garattini, S., van Bekkum, D.W. (eds) The Importance of Animal Experimentation for Safety and Biomedical Research. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1904-4_12
Download citation
DOI: https://doi.org/10.1007/978-94-009-1904-4_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7349-3
Online ISBN: 978-94-009-1904-4
eBook Packages: Springer Book Archive